The aim of this analysis was to develop a population pharmacokinetic model for Emfilermin ( recombinant human leukaemia inhibitory factor , r-hLIF ) following subcutaneous administration to healthy postmenopausal women and to infertile patients undergoing in vitro fertilization and embryo transfer ( IVF-ET ) .
